The ScheBo Biotech Tumor M2-PK Stool Test is a highly sensitive and specific metabolic biomarker for colorectal cancer screening which is independent of 'Faecal Occult Blood' (FOB). The Tumor M2-PK Stool Test is a totally new approach, which is much more sensitive than previous laboratory bowel cancer screening tests. Previously, only non-specific tests for blood in the stool could be used to give an indication of an existing bowel cancer or its precursors. With the new ELISA method for Tumor M2-PK in the stool it's now possible to detect bleeding or non-bleeding bowel cancers, as well as polyps, with high sensitivity and specificity. The test is more accurate because it is not dependent on occult blood.

The main advantages of the ScheBo Biotech Tumor M2-PK Stool Test are:

• High sensitivity
• High specificity
• Not dependent on occult blood
• Detects bleeding or non-bleeding bowel polyps, especially >1cm
• Detects bleeding or non-bleeding bowel tumors
• Not affected by specific foods
• No special diet required
• No false results from haemorrhoids or other sources of blood in the bowel
• A single pea-sized sample is sufficient

The ScheBio Biotech Tumor M2-PK EDTA Plasma Test detects a metabolic state highly specific for a variety of tumors. Its superior usefulness was demonstrated in diagnosis and monitoring of different cancer types. It's the first reliable tumor marker for renal cell carcinoma.

The following tumors are detected with the Tumor M2-PK EDTA Plasma Test:

• Renal cell carcinoma
• Colorectal cancer
• Gastric cancer
• Oesophageal carcinoma
• Lung cancer
• Breast cancer
• Pancreatic cancer